Welcome to our dedicated page for GeoVax Labs Warrants news (Ticker: GOVXW), a resource for investors and traders seeking the latest updates and insights on GeoVax Labs Warrants stock.
GeoVax Labs, Inc. (OTCQB: GOVX) is a clinical-stage biotechnology company specializing in developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers.
Utilizing novel proprietary platforms like the modified vaccinia ankara - virus-like particle (MVA-VLP) vaccine platform, GeoVax's pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and gene-directed therapy for head and neck cancers.
Additional research programs focus on preventive vaccines against infectious diseases like Monkeypox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, along with immunotherapies for various solid tumors.
Recent achievements include positive initial safety and immune response findings from a Phase 2 clinical trial evaluating GEO-CM04S1, the COVID-19 vaccine, as a heterologous booster in 63 healthy adults who previously received the Pfizer or Moderna mRNA vaccine. The trial has demonstrated statistically significant increases in neutralizing antibody responses against multiple SARS-CoV-2 variants.
GeoVax Labs, Inc. (Nasdaq: GOVX) has initiated vaccine dosing in the Phase 2 trial of its COH04S1, a multi-antigenic SARS-CoV-2 vaccine targeting both spike and nucleocapsid proteins. This trial aims to evaluate COH04S1 as a universal booster for current FDA-approved vaccines. The Phase 1 portion focused on safety and immunogenicity in healthy individuals, while Phase 2 involves 60 previously vaccinated participants. Positive expectations arise from COH04S1's potential to offer enhanced immune responses against variants like Omicron. Results are anticipated in early 2022.
GeoVax Labs has received a Notice of Allowance for its patent application aimed at developing a vaccine for malaria, utilizing modified vaccinia Ankara (MVA) vectors. This innovative platform targets multiple stages of the malaria parasite, addressing a significant public health crisis with 228 million infections and 405,000 deaths annually. GeoVax's focus remains on its COVID-19 vaccine in Phase 2 trials, alongside cancer therapies. The company emphasizes its dedication to advancing vaccine innovations to enhance public health globally.
GeoVax Labs (NASDAQ: GOVX) presented promising preclinical results for its investigational vaccines against Sudan and Marburg viruses at the World Vaccine & Immunotherapy Congress. Using the GV-MVA-VLP platform, the vaccines provided 100% protection in lethal guinea pig models and safeguarded nonhuman primates from severe symptoms and death. This efficacy, alongside the evident immune responses, underscores the potential for further clinical development. The research received federal funding, signaling a commitment to advancing vaccine safety and effectiveness against hemorrhagic fevers.
GeoVax Labs (Nasdaq: GOVX) is advancing its investigational universal vaccine, GEO-CM02, to combat evolving SARS-CoV-2 variants, including Omicron. At the World Vaccine & Immunotherapy Congress, Chief Scientific Officer Mark J. Newman highlighted the vaccine's broad immune response potential, leveraging their GV-MVA-VLP™ platform. The vaccine aims to induce protection against multiple coronavirus proteins, promising enhanced durability and efficacy. Ongoing studies reported positive results in small animal trials, showing immune responses after a single dose, crucial in tackling emerging variants.
GeoVax Labs, Inc. (Nasdaq: GOVX) recently presented data on its COVID-19 vaccine candidate, GEO-CM02, at the Vaccine World Asia Congress. Developed using the GV-MVA-VLP™ platform, this vaccine aims to provide broader immunity against evolving SARS-CoV-2 variants by targeting multiple structural proteins. Efficacy studies show promise, including protection against the Beta variant. Additionally, GeoVax's collaboration with City of Hope on the multi-antigenic vaccine COH04S1 is progressing through Phase 2 trials, reinforcing its commitment to combat COVID-19 in vulnerable populations.
GeoVax Labs, Inc. (Nasdaq: GOVX) announced the issuance of a Notice of Allowance for Patent Application No. 16/068,527 for a novel immunotherapy development targeting tumor-associated antigens. This patent expands GeoVax's intellectual property portfolio to over 70 granted or pending applications. The company is progressing with its MVA-VLP-MUC1 immunotherapy candidates, which show promise against several cancers, and has acquired rights to Gedeptin®, a patented product for solid tumors in clinical trials. The advancements signal significant prospects for future therapeutic applications.
GeoVax Labs, Inc. (Nasdaq: GOVX) announced its participation in significant scientific conferences. On November 17, Chief Scientific Officer Mark Newman, PhD, will present on a universal coronavirus vaccine at the Vaccine World Asia Congress. At the World Vaccine & Immunotherapy Congress in San Diego from November 30 to December 2, he will discuss VLP-based COVID-19 vaccine development, while Senior Scientist Mary Hauser, PhD, will present on vaccines against hemorrhagic fevers.
GeoVax specializes in developing vaccines for infectious diseases and cancer using advanced platforms.
GeoVax Labs, Inc. (GOVX) reported a net loss of $1.95 million ($0.31 per share) for Q3 2021, a significant increase from $570,648 ($0.73 per share) in Q3 2020. The company has entered an exclusive licensing agreement with City of Hope for COH04S1, a COVID-19 vaccine candidate, currently undergoing a Phase 2 trial for immunocompromised patients. GeoVax also acquired Gedeptin®, a novel gene therapy for solid tumors, with a Phase 1/2 trial enrolling patients. Cash balances rose to $18.1 million, aided by stock sales and warrant exercises.
GeoVax Labs (Nasdaq: GOVX) announced an exclusive licensing agreement with City of Hope to develop a multi-antigenic SARS-CoV-2 vaccine, COH04S1, aimed at immunocompromised patients. Currently in a Phase 2 trial, the vaccine could serve as a booster against COVID-19 worldwide. COH04S1 uniquely includes both spike and nucleocapsid proteins, prompting a rapid immune response. The agreement enhances GeoVax's pipeline alongside its MVA-based vaccine technology, targeting multiple infectious diseases. Financial terms remain undisclosed, with a conference call for financial results scheduled on Nov. 11, 2021.
GeoVax Labs, Inc. (GOVX) announced it will release Q3 2021 financial results on November 11, 2021, post-market. A conference call will follow at 4:30 PM ET for management to discuss the results and corporate updates.
The company is focused on developing immunotherapies and vaccines for infectious diseases and cancer, utilizing patented platforms like MVA-VLP. Recent advancements include the acquisition of Gedeptin, aimed at treating solid tumors, with a Phase 1/2 trial currently enrolling patients.
FAQ
What is the current stock price of GeoVax Labs Warrants (GOVXW)?
What is GeoVax Labs, Inc. focused on developing?
What recent achievements has GeoVax Labs, Inc. made?
Which diseases are targeted by GeoVax's vaccine development programs?
